Novo Nordisk and the University of Toronto announce joint 200 DKK million investment to address diabetes and chronic disease prevention
24 February 2021 – Novo Nordisk A/S and the University of Toronto (U of T) today announced a DKK 200 million (CAD 40 million) investment to establish the Novo Nordisk Network for Healthy Populations. The network will focus on new ways to support healthier urban populations and will draw on U of T’s leading expertise in public health research and education programmes to impact the global fight against diabetes and other serious chronic diseases. Based at U of T Mississauga, the new network will be a partnership between the Dalla Lana School of Public Health, the Temerty Faculty of Medicine and University of Toronto Mississauga.
Full year 2020: Novo Nordisk's net profit increased by 8% in 2020
3 February 2021 - Lars Fruergaard Jørgensen, president and CEO: "We are very satisfied with the progress on our Strategic Aspirations in 2020 despite the challenges of COVID-19. This was only possible due to the commitment from all our employees. The financial results reflect sales growth in both International Operations and North America Operations driven by more patients using our GLP-1 treatments. Within R&D, key milestones in the fourth quarter were the regulatory submissions of semaglutide 2.4 mg which has the potential to redefine the treatment of obesity. In 2021, we will continue our focus on commercial execution while conducting more late-stage clinical trial programmes than ever to meet the unmet needs of people living with diabetes and other serious chronic diseases."
Novo Nordisk launches new 100% renewable power target for suppliers
21 September - Novo Nordisk today announced an ambitious target to ensure all its direct suppliers supply the company based on 100% renewable power by 2030. Novo Nordisk will work with all existing and new suppliers to meet the target. The plan will be presented in connection with Climate Week NYC hosted this week in association with the United Nations and the City of New York. This commitment is the next step in Novo Nordisk’s ‘Circular for Zero’ environmental strategy, which launched in April 2019 and set an ultimate ambition for the company to have zero environmental impact.
Recycling an insulin pen is a lot harder than it sounds. But might there come a day when all insulin pens can be re-purposed after use? And what more can we do to help solve the world’s growing plastic challenge?